|
Adolopment |
Adoption-Adaptation-Development |
|
AGREE II |
Appraisal of Guidelines for Research and Evaluation Instrument |
|
ANA |
Anti-nuclear antibody |
|
APLA |
Anti-phospholipid antibody |
|
aPTT |
activated partial thromboplastin time |
|
ASH |
American Society of Hematology |
|
BSH |
British Society of Haematology |
|
BSH |
British Society for Haematology |
|
CPG |
Clinical Practice Guideline |
|
DAT |
Direct Antiglobulin test |
|
EPG |
Egyptian Paediatric Clinical Practice Guidelines Committee |
|
EPG CPG |
EPG Clinical Practice Guideline |
|
ERG |
External Review Group |
|
FNAIT |
Fetal / neonatal alloimmune thrombocytopenia |
|
FAST |
Focused assessment with sonography in trauma |
|
GAG |
Guideline Adaptation Group |
|
GDG |
Guideline Development Group |
|
Gp |
Glycoprotein |
|
GPS |
Good practice statement |
|
GRADE |
Grading of Recommendations Assessment, Development and Evaluation |
|
HPA |
Human platelet antibody |
|
HRQoL |
Health related quality of life |
|
ICH |
Intracranial hemorrhage |
|
Igs |
Immunoglobulins |
|
INR |
International normalized ratio |
|
ISTH |
International society of Thrombosis and Hemostasis |
|
ISTH-SSC |
|
|
ITP |
Immune thrombocytopenia |
|
ITP IWG |
ITP international working group |
|
IVIg |
Intravenous immunoglobulin |
|
HDFN |
Haemolytic disease of the fetus and newborn |
|
HSCT |
Haematopoietic stem cell transplant |
|
HL |
Hodgkin lymphoma |
|
Ig |
Immunoglobulin |
|
IHN |
International hemovigilance network |
|
Non-IT |
Non-immune thrombocytopenia |
|
NSAIDs |
Non-steroidal anti-inflammatory drugs |
|
PAR-1 |
protease-activated receptor-1 |
|
PICO |
population, intervention, comparison, and outcomes |
|
PIPOH |
Patient population, intervention, professionals, outcomes, and healthcare context |
|
QoE |
Quality of evidence |
|
RBC |
Red blood cell |
|
RCT |
Randomized-controlled trials |
|
RIGHT |
A Reporting Tool for Practice Guidelines in Health Care |
|
SoR |
Strength of recommendation |
|
WBC |
White blood cells |
|
WBCT |
Whole-body CT |